Menei Philippe, Jadaud Eric, Faisant Nathalie, Boisdron-Celle Michèle, Michalak Sophie, Fournier Dominique, Delhaye Manuel, Benoit Jean-Pierre
Department of Neurosurgery, Centre Hospitalo-Universitaire d'Angers, 49033 Angers Cedex 01, France.
Cancer. 2004 Jan 15;100(2):405-10. doi: 10.1002/cncr.11922.
The authors developed a new method of drug delivery into the brain using implantable, biodegradable microspheres. The strategy was evaluated initially to provide localized and sustained delivery of the radiosensitizer 5-fluorouracil (5-FU) after patients underwent surgical resection of malignant glioma. In this study, the microspheres were implanted by stereotaxy into deeply situated and inoperable brain tumors.
Ten patients with newly diagnosed, inoperable, malignant gliomas were included in the study, and 1 dose of 5-FU was studied (132 mg). After histologic confirmation, a suspension of poly(D-L lactide-co-glycolide) 5-FU-loaded microspheres was implanted by stereotaxy into the tumor in one or several trajectories with one to seven deposits per trajectory. External beam radiation (59.4 grays) was started before postoperative Day 7. Patients were followed by clinical examination, computed tomography scanning, magnetic resonance imaging, and 5-FU assays in blood and cerebrospinal fluid (CSF).
The number of trajectories was adapted to the size and shape of the tumor. Microsphere implantation was tolerated well, except in four patients who received a single trajectory and experienced a transitory worsening of preexisting neurologic symptoms. There were no episodes of edema or hematologic complications. 5-FU was detected in CSF and blood in some patients at very low concentrations. The median overall survival was 40 weeks, with 2 patients who had longer survival (71 weeks and 89 weeks, respectively).
In this study, the authors demonstrated that biodegradable microspheres could be implanted by stereotaxy and were efficient systems for drug delivery into brain tumors. This method may have future applications in the treatment of patients other malignancies.
作者研发了一种使用可植入、可生物降解微球向脑内给药的新方法。该策略最初是在恶性胶质瘤患者接受手术切除后,用于提供放射增敏剂5-氟尿嘧啶(5-FU)的局部持续递送。在本研究中,通过立体定向将微球植入深部且无法手术切除的脑肿瘤中。
10例新诊断的、无法手术切除的恶性胶质瘤患者纳入本研究,研究1剂5-FU(132mg)。组织学确诊后,将负载5-FU的聚(D-L丙交酯-共-乙交酯)微球悬浮液通过立体定向植入肿瘤,采用一个或几个轨迹,每个轨迹有1至7个植入点。术后第7天前开始进行外照射(59.4戈瑞)。通过临床检查、计算机断层扫描、磁共振成像以及血液和脑脊液(CSF)中的5-FU检测对患者进行随访。
轨迹数量根据肿瘤的大小和形状进行调整。微球植入耐受性良好,但有4例接受单轨迹植入的患者出现原有神经症状短暂恶化。未发生水肿或血液学并发症。部分患者的脑脊液和血液中检测到极低浓度的5-FU。中位总生存期为40周,有2例患者生存期更长(分别为71周和89周)。
在本研究中,作者证明可通过立体定向植入可生物降解微球,且其是向脑肿瘤给药的有效系统。该方法未来可能应用于其他恶性肿瘤患者的治疗。